实践使得不完美:在患上阿尔茨海默病的高风险人群中,对实践的隐性干扰更强
Shao-Min Hung1,2,3, Sara W Adams4, Cathleen Molloy5
1Waseda Institute for Advanced Study, Waseda University, Tokyo, Japan. smhung@aoni.waseda.jp.
GeroScience
|October 10, 2023
概括
患阿尔茨海默病的高风险个体,与低风险个体不同,对实践的隐性干扰增加. 这种注意力和感知的差异可能是早期认知变化的信号.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 生物标志物 生物标志物
背景情况:
- 早期发现阿尔茨海默病 (AD) 对于干预和规划至关重要.
- 行为生物标志物提供了可访问的查方法.
- 之前的研究将高AD风险 (通过脑脊髓液粉样蛋白/tau比率表示) 与在需要注意力的任务中隐性干扰联系起来.
研究的目的:
- 调查注意力如何调节对阿尔茨海默病高低风险个体的隐性干扰.
- 检查实践对这些群体内隐性干扰效应的影响.
主要方法:
- 分析了两项涉及高风险和低风险个体的连续实验.
- 对隐性干扰的实践影响的评估.
- 在任务负载转移期间,隐性干扰,实践和电脑电图 (EEG) 的α事件相关脱同步 (ERD) 之间的相关性分析.
主要成果:
- 高风险和低风险组都表现出显著的实践效应.
- 实践效应与高风险个体的隐性干扰增加相关,但低风险个体的干扰减少.
- 低风险个体在从高任务负载过渡到低任务负载时,表现出隐性干扰和EEGαERD之间的正相关性,这表明注意力减少.
结论:
- 注意力显著影响隐性干扰,在阿尔茨海默病高风险和低风险个体之间观察到不同的模式.
- 实践对干扰的不同影响表明高风险个体的早期感知和注意力差异.
- 这些发现突显了行为和神经生理学标记在早期阿尔茨海默氏症风险评估中的潜力.
相关概念视频
01:26Alzheimer's Disease: Overview
503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
01:22Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
01:16Interference and Decay
149
Forgetting is a complex cognitive phenomenon influenced by several factors, among which interference and decay are particularly prominent. These processes explain why individuals often struggle to retrieve specific information from memory, leading to lapses in recall that can be observed in everyday situations.
Interference occurs when competing memories hinder the retrieval of particular information. It can be classified into two types: proactive and retroactive interference. Proactive...
Interference occurs when competing memories hinder the retrieval of particular information. It can be classified into two types: proactive and retroactive interference. Proactive...
149
01:30Dementia
121
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
121
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
132
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
132